PT - JOURNAL ARTICLE AU - Rebecca L. Pinals AU - Francis Ledesma AU - Darwin Yang AU - Nicole Navarro AU - Sanghwa Jeong AU - John E. Pak AU - Lili Kuo AU - Yung-Chun Chuang AU - Yu-Wei Cheng AU - Hung-Yu Sun AU - Markita P. Landry TI - Rapid SARS-CoV-2 Detection by Carbon Nanotube-Based Near-Infrared Nanosensors AID - 10.1101/2020.11.02.20223404 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.02.20223404 4099 - http://medrxiv.org/content/early/2020/11/04/2020.11.02.20223404.short 4100 - http://medrxiv.org/content/early/2020/11/04/2020.11.02.20223404.full AB - To effectively track and eliminate COVID-19, it is critical to develop tools for rapid and accessible diagnosis of actively infected individuals. Here, we introduce a single-walled carbon nanotube (SWCNT)-based optical sensing approach towards these ends. We construct a nanosensor based on SWCNTs noncovalently functionalized with ACE2, a host protein with high binding affinity for the SARS-CoV-2 spike protein. Presence of the SARS-CoV-2 spike protein elicits a robust, two-fold nanosensor fluorescence increase within 90 min of spike protein exposure. We characterize the nanosensor stability and sensing mechanism, and passivate the nanosensor to preserve sensing response in saliva and viral transport medium. We further demonstrate that these ACE2-SWCNT nanosensors retain sensing capacity in a surface-immobilized format, exhibiting a 73% fluorescence turn-on response within 5 s of exposure to 35 mg/L SARS-CoV-2 virus-like particles. Our data demonstrate that ACE2-SWCNT nanosensors can be developed into an optical tool for rapid SARS-CoV-2 detection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementWe acknowledge support of the IGI LGR ERA and Citris/Banatao Seed Funding. We acknowledge support of an NIH NIDA CEBRA award # R21DA044010 (to M.P.L.), a Burroughs Wellcome Fund Career Award at the Scientific Interface (CASI) (to M.P.L.), the Simons Foundation (to M.P.L.), a Stanley Fahn PDF Junior Faculty Grant with Award # PF-JFA-1760 (to M.P.L.), a Beckman Foundation Young Investigator Award (to M.P.L.), and a DARPA Young Investigator Award (to M.P.L.). M.P.L. is a Chan Zuckerberg Biohub investigator. R.L.P., F.L., and D.Y. acknowledge the support of NSF Graduate Research Fellowships (NSF DGE 1752814).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Biofluids were sourced from suppliers, obtained with informed consent from all donors and in accordance with the relevant guidelines and regulations. The below definitions provided by UC Berkeley have established that the enclosed work is exempt from IRB oversight because while we use biospecimens, but do not intervene/interact with the human subjects. The University of California Berkeley has determined our enclosed study is not human subjects research as defined by federal regulations at 45 CFR 46.102 (DHHS) and/or 21 CFR 50.3 (FDA). Per 45 CFR 46.102, human subjects research must be research and involve human subjects according to the below definitions. Research means a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge. Our work does not perform the above functions on human subjects. Human subject means a living individual about whom an investigator conducting research: 1. Obtains information or biospecimens through intervention or interaction with the individual, and uses, studies, or analyzes the information or biospecimens. or 2. Obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens. Our work does not perform the above functions on human subjects. Per 21 CFR 50.3, human subjects research must be a clinical investigation and involve human subjects according to the below definitions: Clinical investigation means any experiment that involves a test article and one or more human subjects and that either is subject to requirements for prior submission to the Food and Drug Administration under section 505(i) or 520(g) of the act, or is not subject to requirements for prior submission to the Food and Drug Administration under these sections of the act, but the results of which are intended to be submitted later to, or held for inspection by, the Food and Drug Administration as part of an application for a research or marketing permit. Human subject means an individual who is or becomes a participant in research, either as a recipient of the test article or as a control. A subject may be either a healthy human or a patient. Note that for device studies, this includes an individual on whom or on whose specimen an investigational device is used. Our work does not perform the above functions on human subjects. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.